Sponsors (5)
The bill strengthens FDA oversight, transparency, and scientific rigor for GRAS substances—improving consumer safety and public trust—but does so at the cost of higher compliance burdens, fees, and potential delays or product disruptions that disproportionately affect small food businesses and may raise prices for consumers.
Consumers — including pregnant women and children — face lower risk from unsafe food ingredients because the bill raises evidence requirements for GRAS determinations, requires periodic reassessments, allows revocation of prior no‑objection statements, and enables FDA to require updated exposure and cumulative‑effects data.
The public gains greater transparency and trust because FDA must post GRAS notices, supporting data, written determinations and revocations, open a 60‑day public comment period, and strengthen conflict‑of‑interest rules for reviewers.
Manufacturers and petitioners get clearer regulatory standards and defined terms (e.g., carcinogenicity, reproductive toxicity, food‑contact substance) and a clearer 'not to object' process, improving legal certainty for compliant firms once FDA issues determinations.
Small food manufacturers and other firms will face substantially higher compliance costs because they must assemble expert reviews, extensive safety data, and repeated reassessments to meet the new GRAS standards.
Consumers may see reduced product availability, forced reformulations, or higher prices if firms withdraw ingredients, reformulate products, or pass compliance and fee costs onto consumers.
The requirement to await FDA review (including statutorily referenced review windows and possible extensions) plus new fees could slow market entry and deter innovation, especially for smaller firms.
Based on analysis of 6 sections of legislative text.
Tightens GRAS definition, creates mandatory FDA GRAS notice/review and periodic reassessments, and expands fees to recover FDA costs.
Rewrites how the FDA treats substances added to food by narrowing and formalizing the "generally recognized as safe" (GRAS) concept, creating a mandatory GRAS notice and review process for new uses and newly marketed substances, and requiring periodic safety reassessments. It also updates definitions used in FDA law and expands fee authorities so FDA can recover costs for GRAS notices and reassessments.
Official title: To amend the Federal Food, Drug, and Cosmetic Act to require notification to the Food and Drug Administration prior to use of substances as generally recognized as safe, reassessment of the safety of certain substances marketed as generally recognized as safe, provide resources for reviews and reassessments, and for other purposes.
Introduced August 12, 2025 by Frank Pallone · Last progress August 12, 2025